<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478306</url>
  </required_header>
  <id_info>
    <org_study_id>DR2</org_study_id>
    <secondary_id>2015-003955-23</secondary_id>
    <nct_id>NCT03478306</nct_id>
  </id_info>
  <brief_title>Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm</brief_title>
  <official_title>Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of melatonin 4 mg on circadian rhythm and visual function of
      patients with diabetes mellitus. Half of the patients will receive melatonin (arm-1) and the
      other half will receive placebo (arm-2), both groups in 3 weeks. After a week of washout, the
      patients will cross over to the other treatment arm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Double-blind, randomized, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Melatonin and placebo tablets are identicle in terms of taste, colour, tablet-size etc. The tablets are packed and masked by external manufacturer.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of diabetic retinopathy, oscillary potential</measure>
    <time_frame>3 weeks</time_frame>
    <description>Progression of diabetic retinopati measured with electroretinography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-illumination pupillary light response</measure>
    <time_frame>3 weeks</time_frame>
    <description>Melanopsin-mediated pupillary response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circadian photoentrainment</measure>
    <time_frame>3 weeks</time_frame>
    <description>Salivary melatonin level and sleep assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal structure</measure>
    <time_frame>3 weeks</time_frame>
    <description>Retinal structure assessed by optical coherence tomography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Melatonin</condition>
  <condition>Circadian Dysrhythmia</condition>
  <condition>Circadian Rhythm Sleep Disorder, Unspecified Type</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 4 mg Tablet</intervention_name>
    <description>Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients

          -  Age range 40-75 years

          -  Participant should be legally competent

        Exclusion Criteria:

          -  Other known eye disease.

          -  Eye disease manifestation during ocular examination.

          -  Competing neurologic and systemic conditions affecting retina.

          -  Use of any drugs influencing pupillary light reflex and sleep pattern.

          -  Refractive error with need of &gt; 6 diopter lenses.

          -  Pregnancy

          -  Alcohol consumption during the trial

          -  Lack of cooperation

          -  Allergy to melatonin and/or preservatives in melatonin and placebo

          -  Reduced hepatic function

          -  Fluvoxamin intake due to drug interaction

          -  Consumption of Alpha-1 and beta-1 adnergic antagoists.

          -  Alcohol consumption during treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shakoor Ba-Ali</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Rigshospitalet-Glostrup</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shakoor Ba-Ali, MD</last_name>
    <phone>+4531614923</phone>
    <email>shakoor@shakoor.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology, Rigshospitalet-Glostrup</name>
      <address>
        <city>Glostrup</city>
        <state>RegionH</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shakoor Ba-Ali</last_name>
      <phone>+4531614923</phone>
      <email>shakoor@shakoor.dk</email>
    </contact>
    <investigator>
      <last_name>Shakoor Ba-Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Shakoor Ba-Ali</investigator_full_name>
    <investigator_title>Principal Investigator, Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

